[PMETAL] QoQ Quarter Result on 30-Jun-2022 [#2]

Stock
[PMETAL] PRESS METAL ALUMINIUM HOLDINGS BERHAD
Announcement Date
25-Aug-2022
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2022
Quarter
30-Jun-2022 [#2]
Profit Trend
QoQ- -2.81%
YoY- 60.1%
Quarter Report
Latest QR
Upcoming QR
PMETAL's Result
PMETAL's Financial Summary
View:
Show?
Quarter Result
31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 CAGR
Revenue 3,071,677 3,918,366 3,845,189 4,007,718 3,920,818 3,365,858 2,886,830 4.22%
PBT 392,801 346,526 449,502 566,199 608,701 389,650 394,000 -0.20%
Tax -37,442 -4,101 -57,332 -62,205 -66,548 -24,097 -22,795 39.25%
NP 355,359 342,425 392,170 503,994 542,153 365,553 371,205 -2.86%
-
NP to SH 281,972 272,209 315,804 409,174 421,017 285,815 283,333 -0.32%
-
Tax Rate 9.53% 1.18% 12.75% 10.99% 10.93% 6.18% 5.79% -
Total Cost 2,716,318 3,575,941 3,453,019 3,503,724 3,378,665 3,000,305 2,515,625 5.25%
-
Net Worth 6,803,211 6,674,090 5,850,128 5,760,191 3,230,487 3,876,585 3,392,011 59.10%
Dividend
31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 CAGR
Div 143,441 144,193 144,193 144,004 121,143 80,762 80,762 46.71%
Div Payout % 50.87% 52.97% 45.66% 35.19% 28.77% 28.26% 28.50% -
Equity
31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 CAGR
Net Worth 6,803,211 6,674,090 5,850,128 5,760,191 3,230,487 3,876,585 3,392,011 59.10%
NOSH 8,239,617 8,239,617 8,239,617 8,239,617 8,076,219 8,076,219 8,076,219 1.34%
Ratio Analysis
31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 CAGR
NP Margin 11.57% 8.74% 10.20% 12.58% 13.83% 10.86% 12.86% -
ROE 4.14% 4.08% 5.40% 7.10% 13.03% 7.37% 8.35% -
Per Share
31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 CAGR
RPS 37.47 47.56 46.67 48.70 48.55 41.68 35.74 3.20%
EPS 3.44 3.30 3.83 4.97 5.21 3.54 3.51 -1.33%
DPS 1.75 1.75 1.75 1.75 1.50 1.00 1.00 45.26%
NAPS 0.83 0.81 0.71 0.70 0.40 0.48 0.42 57.54%
Adjusted Per Share Value based on latest NOSH - 8,239,617
31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 CAGR
RPS 37.28 47.56 46.67 48.64 47.58 40.85 35.04 4.22%
EPS 3.42 3.30 3.83 4.97 5.11 3.47 3.44 -0.38%
DPS 1.74 1.75 1.75 1.75 1.47 0.98 0.98 46.67%
NAPS 0.8257 0.81 0.71 0.6991 0.3921 0.4705 0.4117 59.10%
Price Multiplier on Financial Quarter End Date
31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 CAGR
Date 31/03/23 30/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 -
Price 4.87 4.88 4.04 4.76 6.20 5.78 5.74 -
P/RPS 13.00 10.26 8.66 9.77 12.77 13.87 16.06 -13.15%
P/EPS 141.57 147.71 105.41 95.73 118.93 163.32 163.61 -9.20%
EY 0.71 0.68 0.95 1.04 0.84 0.61 0.61 10.66%
DY 0.36 0.36 0.43 0.37 0.24 0.17 0.17 64.98%
P/NAPS 5.87 6.02 5.69 6.80 15.50 12.04 13.67 -43.11%
Price Multiplier on Announcement Date
31/03/23 31/12/22 30/09/22 30/06/22 31/03/22 31/12/21 30/09/21 CAGR
Date 30/05/23 24/02/23 29/11/22 25/08/22 30/05/22 25/02/22 26/11/21 -
Price 4.73 5.20 4.80 4.89 5.50 6.75 5.57 -
P/RPS 12.62 10.93 10.29 10.04 11.33 16.20 15.58 -13.11%
P/EPS 137.50 157.40 125.24 98.34 105.50 190.73 158.77 -9.15%
EY 0.73 0.64 0.80 1.02 0.95 0.52 0.63 10.33%
DY 0.37 0.34 0.36 0.36 0.27 0.15 0.18 61.73%
P/NAPS 5.70 6.42 6.76 6.99 13.75 14.06 13.26 -43.07%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment